



Clinical case of *Cor triatriatum* in a patient with CHA₂DS₂VASc 1-point atrial fibrillation

Caso clínico de *Cor triatriatum* en un paciente con fibrilación auricular CHA₂DS₂VASc de 1 punto

Ana G Múnera E,* Juan S Rodríguez Z,[‡] Natalia Correa V,[§] Jorge A Bermúdez M[¶]

Keywords:

Cor triatriatum, atrial fibrillation, congenital cardiac anomaly.

Palabras clave:

Cor triatriatum, fibrilación auricular, anomalía cardíaca congénita.

ABSTRACT

Cor triatriatum sinistrum (CTS) is a rare congenital cardiac anomaly with an incidence of 0.1% of all hereditary heart diseases, and its finding is more infrequent in adulthood. It is characterized by presenting a left atrium divided into two chambers by a fibromuscular membrane that may have or not have fenestrations. It has been reported that severe obstruction is indicated by maximum Doppler velocity greater than 2 m/s or a trans-membranous pressure > 10 mmHg. In this article, we present the case of a 68-year-old male patient, who presented *de novo* an atrial fibrillation episode in the context of infectious disease, with a transesophageal echocardiogram showing CTS and a CHA₂DS₂VASc score of 1 point, raising the question of whether it should be anticoagulated, given that the evidence in this setting is limited.

RESUMEN

El *Cor triatriatum sinistrum* (CTS) es una anomalía cardíaca congénita rara con una incidencia del 0.1% del total de las cardiopatías congénitas y aún más infrecuente es su hallazgo en la edad adulta; se caracteriza por presentar una aurícula izquierda dividida en dos cámaras por una membrana fibromuscular que puede presentar o no fenestraciones. Se ha informado que la obstrucción grave está indicada por una velocidad Doppler máxima superior a 2 m/s o una presión transmembrana > 10 mmHg. En este artículo presentamos el caso de un paciente masculino de 68 años, quien presenta episodio de fibrilación auricular de novo en el contexto de cuadro infeccioso, con ecocardiograma transesofágico que evidencia CTS, con un puntaje de CHA₂DS₂VASc 1 punto, generando la interrogante si debía ser anticoagulado, dado que la evidencia en este tema es limitada, finalmente tomando la decisión de anticoagulación con DOACS.

INTRODUCTION

Cor triatriatum sinistrum (CTS) is a congenital heart anomaly in which the left atrium is divided into a «posterior superior» and an «anteroinferior» chamber by a fibromuscular membrane that usually contains one or more fenestrations that allow the passage of the blood.¹ First described in 1868 by Church² and its echocardiographic characteristics described by Ostman-Smith in 1984³ where they specify that, generally, the chamber into which the pulmonary veins drain is dorsal and obliquely inferior to the chamber of the left ventral atrium with the subdivided membrane bulging

upwards and forwards, although this is not always true. Furthermore, the most common site for a single membrane defect was inferior and medial behind the posteromedial commissure of the mitral valve. There is a classification according to Loeffler that divides the CTS into types 1, 2 and 3. Type 1 is characterized by the lack of communication in the membrane itself, type 2 due to having one or more small perforations in the membrane, and type 3 due to a wide opening.⁴ It represents 0.1-0.4% of all congenital heart malformations.⁵ It generally involves the left atrium in approximately 83% and rarely the right atrium *Cor triatriatum dexter* (CTD).⁶ The clinical manifestations

* Fellow American College of Cardiology (FACC) & Inter-American Society of Cardiology (IASC). Non-Invasive Cardiology Service Hospital General de Medellín, Colombia.
[‡] Fellow in Internal Medicine, Universidad de Cartagena, Medellín, Colombia.
[§] Medicine student, Universidad de Antioquia, Medellín, Colombia.
[¶] Internal Medicine Service Hospital General de Medellín, Colombia.

Received: 02/08/2021
Accepted: 12/11/2021

How to cite: Múnera EAG, Rodríguez ZJS, Correa VN, Bermúdez MJA. Clinical case of *Cor triatriatum* in a patient with CHA₂DS₂VASc 1-point atrial fibrillation. Cardiovasc Metab Sci. 2022; 33 (1): 21-25. <https://dx.doi.org/10.35366/104034>

depend on the degree of obstruction of the pulmonary venous return and vary from asymptomatic to pulmonary hypertension.⁷ Surgical management is indicated in patients with a significant obstruction. This clinical case presents a patient with a complicated urinary tract infection (UTI), *de novo* atrial fibrillation (AF) CHA₂DS₂VASc 1 point, and, as an incidental finding on echocardiogram, a CTS.

CASE PRESENTATION

A 68-year-old male patient, native from Venezuela, mixed-race, have a history of benign prostatic hyperplasia being managed with Tamsulosin 0.4 mg orally every day. The patient is a heavy smoker (pack-year 50), who consulted for one day of evolution of atypical chest pain that began at rest, oppressive, of moderate intensity, not irradiated, lasting 30 minutes, self-limited, associated with palpitations, without vasovagal symptoms. Concomitantly, the patient presented obstructive and irritative urinary symptoms. An electrocardiogram was performed, reporting AF with a rapid ventricular response, administered metoprolol tartrate 100 mg PO single dose, and redirected to our institution. On admission, clinically stable, arrhythmic, tachycardic heart sounds, without murmurs, with pulse deficit, without the

presence of congestive or low output signs. The following tests and diagnostic aids were requested (*Table 1 and Figure 1*).

Chest radiography on admission: no pathological findings (*Figure 2*).

A *de novo* initial diagnosis of complicated UTI and paroxysmal AF was made with CHA₂DS₂VASc 1 point and HAS-BLED 1 point. Empirical antibiotic management was initiated according to institutional guidelines with aztreonam and blood cultures, urine culture, renal ultrasound, Holter, and transesophageal echocardiography were requested to define possible cardioversion and anticoagulation.

Transthoracic and transesophageal echocardiography

Findings: Moderate dilation of the left atrium with a moderate increase in left atrial volume. Small left atrial appendage, without thrombi, with average Doppler velocities. A membrane's presence in the left atrium divides the cavity into two chambers, one containing the left atrial appendage and continuing towards the left ventricle and another chamber containing the pulmonary veins. This membrane does not present obstruction to flow due to two fenestrations that communicate in both chambers. *Cor triatriatum sinistrum* type 2.

Table 1: Laboratory tests.

Hemoglobin	14.3 mg/dL (13-17)	pH	7.432
Hematocrit	43% (39-52)	pCO ₂	32.9
Leukocytes	20.100 (3.600-10.200)	pO ₂	64.3
Neutrophiles	89% (45-65%)	HCO ₃	21.4
International normalized ratio	1.27 (0.5-1.5)	BE	-2.9
Thyroid stimulating hormone	1.4 (0.465-4.68)	Lactate	1.5
C-reactive protein	38.9 (< 1)	Proteins	100
Troponin #1	0.041 (upper limit 0.034)	Leukocytes	15 × cap
Troponin #2	0.059 (upper limit 0.034)	Erythrocytes	4-6 × cap
Sodium	136 (137-145)	Bacteria	Low amount
Potassium	4.0 (3.5-5.1)	Aspartate aminotransferase	31.6 (17-59)
Magnesium	2.0 (1.6-2.3)	Alanine aminotransferase	19 (< 50)
Electrocardiogram on admission: arrhythmic rhythm, variable RR interval, normal axis, heart rate 110 bpm, absent P wave, baseline variation.			




Figure 1: Electrocardiogram.

The other cardiac structures were typical. See supplementary data for video material and their explanations (Figure 3).

24-hour Holter EKG: baseline sinus rhythm, normal PR interval, QRS complex, and QTc interval. It alternates with multiple episodes of AF with a rapid ventricular response, with pauses after AF cessation. Some episodes of AF with aberration (Ashman phenomenon). Some suggestive episodes of atrial flutter. A mild increase in supraventricular and ventricular automatism (Figure 4).

Report of renal ultrasound finding a prostate enlargement (vol. 95.8 cm³) and a positive blood culture for *E. coli* ESBL +. Antibiotic management was adjusted according to the antibiogram. The case is evaluated in conjunction with electrophysiology, considering anticoagulation due to cardiac anomaly. Subsequently, the patient resolved bacteremia associated with the UTI and was discharged with a strategy of rate control and anticoagulation with DOAC (direct oral anticoagulant) and outpatient control with Cardiology and Urology.

DISCUSSION

Cor triatriatum (CT) is a rare congenital heart defect whose incidence is estimated to correspond to 0.1% of all congenital heart disease.⁵ The sinistrum variant is the most frequent and has a more significant association

with AF and cerebrovascular attack than CTD.⁶ The communication between the separate atrial cavities can be wide, small, or null, depending on the fenestrations' size, presenting as mitral stenosis, generating increased pressure and pulmonary vascular resistance, giving rise to pulmonary arterial hypertension.⁸ In the literature, symptoms have been attributed to CT only if the transmembrane pressure is > 10 mmHg, and these consist of fatigue, dyspnea, chest pain, palpitations, syncope, exercise intolerance, or even arrhythmias.⁹ As a diagnostic method, color Doppler echocardiography is the non-invasive modality of choice to identify CT and its hemodynamic impact and recognize associated congenital anomalies and the transmembrane gradient.¹⁰ Surgical treatment should be considered when the hemodynamic behavior of the membrane resembles mitral stenosis.¹¹ On the other hand, an incidence of 14.65 vs 12.5% of AF in CTS and CTD, respectively, has been reported in the literature.⁶ This association is due to the distortion of the architecture and derangement of the muscle fibers in the left atrium, producing remodeling, mechanical and electrical alterations, which ultimately predispose to arrhythmias and thrombus formation.¹² The three pillars of AF management are rate control, rhythm control, and anticoagulation. The latter is defined according to the CHA₂DS₂VASc



Figure 2: Chest radiography.




Figure 3: Transthoracic and transesophageal echocardiography. The Arrow points to the membrane that divides the left atrium. **A)** Transthoracic echocardiography, parasternal long axis showing membrane in the left atrium. **B)** Atrial-focused Transthoracic echocardiography. **C-E)** Transesophageal image, where the four cardiac cavities are appreciated, in the left atrium, the presence of a membrane that divides is observed. **F)** Three-dimensional image, showing the membrane in the left atrium. LA = left atrium, LV = left ventricle, RA = right atrium, RV = right ventricle.

risk score indicating anticoagulation with 2 points in men and 3 points in women. There has been frequent discussion about whether patients with 1-point CHA₂DS₂VASc in men and 2-point in women benefit from anticoagulation. Recently, the European Society of Cardiology (ESC) established a reclassification of the risk of cerebrovascular attack in patients with CHA₂DS₂VASc of 1 point in men and 2 points in women, adding other risk factors such as > 65 years, type 2 diabetes mellitus, persistent or permanent AF, BMI > 30, proteinuria (> 150 mg/24 h), eTFG 1400, positive I/T troponins, enlarged left atrium (volume > 73 mL or diameter > 4.7 cm) and atrial appendage velocity.¹³

In our patient, CTS's diagnosis was made late in the seventh decade of life and incidentally due to its little or no hemodynamic impact. The symptoms are not attributed to this cardiac anomaly but its frequent association with arrhythmias such as AF. During the approach to managing his *de novo* AF to define his criteria for cardioversion, a transesophageal echocardiogram was performed in which CTS was detected. The membrane did not present obstruction flow due to two fenestrations that communicate both chambers, classified as CTS type I. The CHA₂DS₂VASc risk score was performed, obtaining 1 point indicating no need for anticoagulation due to its low risk of present cerebrovascular events. However, since cerebrovascular attack incidence in patients with AF and CTS/CTD is close to 6.5%, in terms of CHA₂DS₂VASc, it is equivalent to a score of 4-5 points, so it is decided to anticoagulant




Figure 4: Holter electrocardiogram.

with DOAC. There are 13 case reports in the literature in which CTS is associated with cerebrovascular events of cardioembolic origin and evidence of blood stasis or thrombus.¹² However, there is still uncertainty about the indication for anticoagulation in this context, given that this cardiac malformation is not frequently considered among the risk factors, which leads to therapeutic dilemmas.

CONCLUSIONS

Cor triatriatum is a rare but increasingly recognized congenital cardiac anomaly. Management of this condition depends on the degree of obstruction between the LA chambers seen mainly on Doppler echocardiography. Physiological alterations are like those that occur in mitral stenosis, with alterations in atrial size, volume, and the presence of AF. Current tools or scales for anticoagulation do not consider these types of structural cardiac malformations, as presented in this case.

REFERENCES

1. Kirklin JW, Blackstone E. Kirklin/Barrat-Boyes cardiac surgery. Philadelphia: Elsevier/Saunders, Cop; 2012.
2. Church WS. Congenital malformation of the heart: abnormal septum in left auricle. Trans Pathol Soc Lond. 1868; 19: 188-190.
3. Ostman SI, Silverman NH, Oldershaw P, Lincoln CA, Shinebourne EA. *Cor triatriatum* sinistrum: diagnostic features on cross sectional echocardiography. Br Heart J. 1984; 51: 211.
4. Lambert J, Oechslin E, Tsang W, Osten MD, Thavendiranathan P. *Cor triatriatum* sinister with secundum atrial septal defect. Case (Phila). 2017; 1 (4): 141-146.

5. Niwayama G. *Cor triatriatum*. *Cor triatriatum*. Am Heart J. 1960; 59: 291-317.
6. Ullah W, Sattar Y, Rauf H, Roomi S, Shah M. A systematic review of a long-forgotten cause of atrial fibrillation and stroke: *Cor triatriatum*. Cureus. 2019; 11 (12):
7. Zipes DP, Libby P, Bonow R, Mann D, Tomaselli G. Braunwald. Tratado de cardiología: Texto de medicina cardiovascular. Spain. Elsevier Health Sciences. 2019.
8. Kimura S, Seki K, Shinbo M, Sutou Y, Lino K, Watanabe H, Itou H. An adult case of *Cor triatriatum* causing congestive heart failure. J Card Fail. 2016; 22 (9): S230.
9. Shen MJ. *Cor triatriatum* in a symptomatic elderly man: can we blame the extra membrane?. J Am Coll Cardiol. 2015; 65 (10 Supplement): A638.
10. Uenishi EK, Arias CI, Pitre L, Rotta CA. Caso clínico de *Cor triatriatum* en el adulto asintomático: diagnóstico ecocardiográfico. Rev Colomb Cardiol. 2020; 27 (3): 175-179.
11. Méndez AB, Colchero T, Garcia J, Vila M, Subirana MT, Sionis A. Unusual case of new-onset heart failure due to *Cor triatriatum* sinister. Eur J Heart Fail. 2012; 15 (2): 237-239.
12. Amara RS, Lalla R, Jeudy J, Hong SN. Cardioembolic stroke in a young male with *Cor triatriatum* sinister: a case report. Eur Heart J-Case Rep. 2020; 4 (3): 1-6.
13. Sulzgruber P, Wassmann S, Semb AG, et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J-Cardiovasc Pharmacother. 2019; 5 (3): 171-180.

Funding/support: No financial support was received for this study.

Conflict of interest: The authors declare no conflict of interest.

Correspondence:

Ana G Múnera E

E-mail: anagm@une.net.com